Inhibition of squalene synthase of rat liver by novel 3' substituted quinuclidines. 1996

F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
ZENECA Pharmaceuticals, Macclesfield, Cheshire, U.K.

Squalene synthase (SQS) is a key enzyme in the biosynthetic pathway for cholesterol and is a target for improved agents to lower plasma levels of low-density lipoprotein (LDL). A series of novel 3' substituted quinuclidines have been discovered as inhibitors of the rat liver microsomal enzyme. In this study, we demonstrate the inhibitory effects in vitro and in vivo, of two examples of the series. When microsomes were preincubated with compounds, before addition of substrate, both 3-(biphenyl-4-yl)quinuclidine (BPQ) and 3-(biphenyl-4-yl)-3-hydroxyquinuclidine (BPQ-OH) were found to cause biphasic inhibition of the enzyme with apparent inhibition constants (K'i) for the sensitive phases of 12 nM and 15 nM, respectively. The K'i values for the insensitive phases were 1.8 microM and 2.9 microM, respectively. The two examples inhibited equally both steps of the SQS-catalysed reaction, as shown by parallel inhibition of 3H+ release and labelled squalene formation from [1-3H]farnesyl pyrophosphate (FPP). BPQ and BPQ-OH were shown to be inhibitors of hepatic sterol synthesis from mevalonate with ED50 values of 10.6 and 7.1 mg/kg, respectively, after acute oral administration to the rat. BPQ-OH was chosen for further study and, to determine its selectivity of effect on the mevalonate pathway in vivo, the effect of a dose of 70 mg/kg on the pattern of labelled mevalonate incorporation into the various lipid fractions of the rat liver was examined. As expected, the incorporation into squalene and sterol products was inhibited by about 70%. An appearance of label in fractions corresponding to farnesyl and geranylgeranylpyrophosphates, as well as the corresponding alcohols, was observed in treated but not control animals. In addition, the administration of compound resulted in the appearance of peaks of mevalonate-derived radioactivity in an acidic fraction believed to represent metabolites of farnesol. Such results are consistent with inhibition of the mevalonate pathway at, and not before, SQS. In contrast, there was a significant increase in the incorporation of labelled mevalonate into ubiquinone 10, and the synthesis of dolichols was apparently unchanged. The results suggest a specific effect of BPQ-OH on rat liver SQS. The compound is, therefore, an interesting lead for further investigation of this class of compounds.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008798 Mevalonic Acid A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions. Mevalonate,Acid, Mevalonic
D011812 Quinuclidines A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group. Quinuclidine
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D013186 Farnesyl-Diphosphate Farnesyltransferase The first committed enzyme of the biosynthesis pathway that leads to the production of STEROLS. it catalyzes the synthesis of SQUALENE from farnesyl pyrophosphate via the intermediate PRESQUALENE PYROPHOSPHATE. This enzyme is also a critical branch point enzyme in the biosynthesis of ISOPRENOIDS that is thought to regulate the flux of isoprene intermediates through the sterol pathway. Squalene Synthetase,FPP-FPP Farnesyl Transferase,Farnesyldiphosphate-Farnesyldiphosphate Farnesyltransferase,Presqualene-Diphosphate Synthase,Squalene Synthase,FPP FPP Farnesyl Transferase,Farnesyl Diphosphate Farnesyltransferase,Farnesyl Transferase, FPP-FPP,Farnesyldiphosphate Farnesyldiphosphate Farnesyltransferase,Farnesyltransferase, Farnesyl-Diphosphate,Farnesyltransferase, Farnesyldiphosphate-Farnesyldiphosphate,Presqualene Diphosphate Synthase,Synthase, Presqualene-Diphosphate,Synthase, Squalene,Synthetase, Squalene,Transferase, FPP-FPP Farnesyl

Related Publications

F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
September 2021, Natural product research,
F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
October 1996, Biochimica et biophysica acta,
F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
February 2008, Archives of biochemistry and biophysics,
F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
March 1995, Phytochemistry,
F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
January 2007, Current atherosclerosis reports,
F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
April 2005, Bioorganic & medicinal chemistry letters,
F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
November 2013, The international journal of biochemistry & cell biology,
F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
September 1992, Archives of biochemistry and biophysics,
F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
August 1999, Archives of biochemistry and biophysics,
F McTaggart, and G R Brown, and R G Davidson, and S Freeman, and G A Holdgate, and K B Mallion, and D J Mirrlees, and G J Smith, and W H Ward
July 2010, The Journal of organic chemistry,
Copied contents to your clipboard!